Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trial.
We carried out a double blind multicentre clinical trial in which 171 patients with advanced breast cancer were randomized to receive tamoxifen (30 mg/day) + bromocriptine (5 mg/day) or tamoxifen + placebo. No difference was found in the overall response rates in the two groups (37.5% for placebo; 38% for bromocriptine) or in subgroups (breast tumours, lymph nodes, lung, bone, skin metastases). Tolerability was good in both groups. Within the limits of the statistical power of the test (80%), our results do not show any benefit when bromocriptine was added to tamoxifen.
Bonneterre
J
J
Centre Oscar Lambret, Lille, France.
Mauriac
L
L
Weber
B
B
Roche
H
H
Fargeot
P
P
Tubiana-Hulin
M
M
Sevin
M
M
Chollet
P
P
Cappelaere
P
P
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D001971:Bromocriptine / Q000008:administration & dosage; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D015337:Multicenter Studies as Topic; D013629:Tamoxifen / Q000008:administration & dosage
D013629:Tamoxifen; D001971:Bromocriptine